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Nearly all HIV PIs and the integrase inhibitor elvitegravir require a pharmacokinetic enhancer in order to achieve
therapeutic plasma concentrations at the desired dose and frequency.Whereas ritonavir has been the only avail-
able pharmacokinetic enhancer formore than a decade, cobicistat has recently emerged as an alternative boost-
ing agent. Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently
were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir.
Since cobicistat is a more selective CYP inhibitor than ritonavir and is devoid of enzyme-inducing properties, dif-
ferences are expected in their interaction profiles with some co-medications. Drugs whose exposure might be
altered by ritonavir but unaltered by cobicistat are drugs primarily metabolized by CYP1A2, CYP2B6, CYP2C8,
CYP2C9 and CYP2C19 or drugs undergoing mainly glucuronidation. Thus, co-medications should be systematic-
ally reviewed when switching the pharmacokinetic enhancer to anticipate potential dosage adjustments.
Introduction
The concept of pharmacokinetic boosting, whereby the metabol-
ism of one drug is inhibited by another drug, was applied early on
to HIV PIs in order to improve their effectiveness and convenience
of use.1 Over the past decade, boosting of PIs has been performed
exclusively by using low doses (100–200 mg/day, except for with
tipranavir) of ritonavir, a potent inhibitor of intestinal and hepatic
cytochrome P450 (CYP) 3A and of P-glycoprotein (P-gp), to in-
crease the absorption and prolong the t1
2
of coadministered PIs.2
The use of ritonavir as a boosting agent presents a number of
disadvantages. Ritonavir has antiviral activity, which raises con-
cern about the development of PI resistance if ritonavir is used
as a booster in non-PI-containing regimens. In addition, ritonavir
is poorly soluble, which limits its coformulation with other agents.
Ritonavir also has issues of tolerability, and it inhibits or induces
other drug-metabolizing enzymes, resulting in numerous
unwanted drug–drug interactions (DDIs).2 Consequently, novel
boosting agents have been investigated.3 Cobicistat, a structural
analogue of ritonavir without antiviral activity and with improved
physicochemical properties, is now available as an alternative
pharmacokinetic enhancer.3,4 Cobicistat inhibits CYP3A with a
potency similar to that of ritonavir.5 Cobicistat, at a dosage of
150 mg once daily, provides bioequivalent exposures of the PIs
atazanavir (300 mg once daily)6 and darunavir (800 mg once
daily)7 and of the integrase inhibitor elvitegravir (150 mg once
daily)8 compared with those observed with 100 mg of ritonavir
once daily. Cobicistat is currently available as a single agent
(Tybostw) or coformulated with atazanavir (Evotazw), darunavir
(Rezolstaw) or elvitegravir (Stribildw, Genvoyaw). Although cobici-
stat (150 mg once daily) and ritonavir (100 mg once daily)
are interchangeable as boosters of drugs metabolized by
CYP3A,9 cobicistat is a more specific CYP3A inhibitor than ritonavir
and has no inducing properties. Consequently, differences are
expected in their interaction profiles with some co-medications.
This commentary summarizes the effects of ritonavir and cobi-
cistat on various CYPs and drug transporters and provides a list of
co-medications predicted to be affected differently and which
may require a dosage adjustment when switching boost-
ing agent.
Effects of ritonavir and cobicistat on
cytochromes and drug transporters
Ritonavir and cobicistat are equally potent inhibitors of CYP3A.4 As
summarized in Table 1, cobicistat is a more selective inhibitor of
CYPs and, when clinically relevant concentrations are considered,
has no inhibitory effects on CYP2C8 and is a weaker inhibitor of
CYP2D6.4
Similarly to ritonavir, cobicistat inhibits the intestinal transpor-
ters P-gp and breast cancer resistance protein (BCRP), thereby
increasing the absorption of coadministered substrates such as
atazanavir, darunavir and tenofovir alafenamide.11 At clinical con-
centrations, ritonavir and cobicistat also inhibit the hepatic trans-
porters organic anion transporting polypeptides (OATPs) and
multiantimicrobial extrusion protein 1 (MATE1), a transporter
involved in the tubular secretion of creatinine.12 Consequently, a
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small increase in serum creatinine with a related decrease in esti-
mated glomerular filtration rate have been reported upon treat-
ment with cobicistat- and ritonavir-based regimens. This effect
has been shown to reflect mainly the inhibition of creatinine
secretion by MATE1 rather than an actual impairment of the
renal function.13 Interestingly, when compared with those
containing ritonavir, cobicistat-containing regimens have consist-
ently shown higher serum creatinine concentrations,6,9,14 even
though they share similar IC50 values for MATE1.
12 Cobicistat
has been shown to be actively transported in the tubular cells
by organic cation transporter 2 (OCT2).12 Therefore, one explan-
ation for the higher serum creatinine is that cobicistat accumu-
lates preferentially in the tubular cells and thus achieves higher
concentrations to inhibit MATE1.12
A key difference between ritonavir and cobicistat is their ability
to activate the pregnane X receptor (PXR), which regulates the
expression of various drug-metabolizing enzymes.15 Cobicistat
was shown to have a limited effect on PXR and therefore is unlikely
to induce drug metabolism.4 Conversely, ritonavir activates PXR
and is known to induce CYP1A2, CYP2B6, CYP2C9 and CYP2C19
and glucuronidation.16–19
Co-medications affected differently by
ritonavir and cobicistat
Based on the previous considerations, drugs undergoing major
metabolism via CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2C19 or
via glucuronidation, with no or minor involvement of CYP3A, are
predicted to be affected differently by ritonavir than by cobicistat.
Co-medications belonging to this category are presented in
Table 2. The list has been established from the Liverpool HIV
drug interaction database,20 which contains information on the
metabolic pathway and related risk of DDI with antiretroviral
drugs for more than 600 co-medications. The differences in the
interaction profiles for ritonavir and cobicistat are summarized
as follows:
- exposure of drugs glucuronidated and/or metabolized by indu-
cible CYPs and without CYP3A involvement are predicted to be
decreased by ritonavir but not affected by cobicistat (e.g.
lamotrigine)
- exposure of drugs glucuronidated and/or metabolized by indu-
cible CYPs to a larger extent than CYP3A are predicted to be
decreased by ritonavir but increased moderately by cobici-
stat (e.g. asenapine)
- exposure of drugs whosemetabolism is subject to induction or
inhibition are predicted to be decreased or increased by ritona-
vir but only increased by cobicistat (e.g. dihydrocodeine)
Importantly, cobicistat is licensed only as a once-daily boosting
agent and therefore might not be able to overcome the effects
of inducers. Thus, cobicistat-boosted regimens are not recom-
mended in presence of efavirenz, etravirine or nevirapine, whereas
coadministration is possible when using, for instance, darunavir
twice daily with ritonavir (Table 2).20
Finally, although cobicistat has no inducing effects per se, it is
also coformulated with elvitegravir, a modest inducer of CYP2C9,
whichmight decrease the exposure of sensitive substrates such as
the anticoagulants. Warfarin is a mixture of enantiomers, which
are metabolized by different CYPs. S-warfarin (more potent) is
metabolized by CYP2C9, whereas R-warfarin is metabolized
by CYP1A2, CYP3A4 and CYP2C19.21 Interestingly, elvitegravir/
cobicistat was shown to decrease the exposure of warfarin, sug-
gesting that CYP2C9 induction by elvitegravir has the stronger
effect on warfarin metabolism compared with CYP3A inhibition
by cobicistat.22
Conclusions
Although cobicistat and ritonavir are interchangeable as boosters
of CYP3A, cobicistat is amore-specific CYP3A inhibitor than ritona-
vir and has no inducing properties. Consequently, co-medications
primarily metabolized by CYP1A2, CYP2B6, CYP2C8, CYP2C9 and
CYP2C19 or mainly glucuronidated are predicted to be affected
differently by ritonavir and cobicistat. Therefore, co-medications
should be systematically reviewed when switching pharma-
cokinetic enhancer in order to anticipate potential dosage
adjustments.
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Table 1. Inhibitory and inducing effects of ritonavir and cobicistat on
cytochromes and drug transporters3,4,10–12
IC50 (mM)
ritonavir cobicistat
Cytochrome
CYP1A2 .25 .25
CYP2B6 2.9 2.8
CYP2C8 2.8 .25
CYP2C9 4.4 .25
CYP2C19 .25 .25
CYP2D6 2.8 9.2
CYP3A4 0.11 0.15
Transporter
P-gp .20 36
BCRP .20 59
OATP1B1 2.05 3.5
OATP1B3 1.83 1.88
MATE1 1.34 1.87
MATE2-K .20 33.5
OAT1 .20 .100
OAT3 8.46 .100
OCT2 20 14
PXR activationa 51% 10%
OAT, organic anion transporter.
aPotential to activate PXR.
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Table 2. Co-medications predicted to be affected differently by ritonavir versus cobicistat pharmacokinetic boosting
Therapeutic class Drug Metabolic pathway/comments Ritonavir Cobicistat
Anaesthetics propofol UGT1A9, UGT1A8+CYP2B6  ↔
Analgesics diamorphine deacetylation+UGT2B7, UGT1A1  ↔
dihydrocodeine CYP2D6+UGT2B7.CYP3A4  
hydromorphone UGT2B7  ↔
morphine UGT2B7, UGT1A1  ↔
pethidine CYP2B6.CYP3A4  
Antibacterials sulfadiazine CYP2C9  ↔
Anticoagulants acenocoumarol CYP2C9.CYP1A2, CYP2C19  ↔
eltrombopag UGT1A1, UGT1A3+CYP1A2, CYP2C8  ↔
phenprocoumon CYP2C9, CYP3A4  
warfarin CYP2C9.CYP1A2, CYP3A4, CYP2C19  
Anticonvulsants lamotrigine UGT1A4  ↔
valproate UGT1A6, UGT1A9, UGT2B7+CYP2C9, CYP2C19  ↔
Antidepressants agomelatine CYP1A2  ↔
bupropion CYP2B6  ↔
duloxetine CYP2D6, CYP1A2  
sertraline CYP2B6.CYP2C9, CYP2C19, CYP2D6, CYP3A4  
Antidiabetics gliclazide CYP2C9.CYP2C19  ↔
glimepiride CYP2C9  ↔
glipizide CYP2C9  ↔
nateglinide CYP2C9.CYP3A4  
rosiglitazone CYP2C8.CYP2C9  ↔
tolbutamide CYP2C9.CYP2C8, CYP2C19  ↔
Antiprotozoals amodiaquine CYP2C8  ↔
atovaquone glucuronidation  ↔
proguanil CYP2C19.CYP3A4  ↔
Antipsychotics asenapine UGT1A4, CYP1A2, CYP3A4  
olanzapine CYP1A2, UGT1A4  ↔
Antiretrovirals efavirenz cobicistat administered 150 mg once daily is not sufficient to
overcome induction by efavirenz, etravirine or nevirapine
a b
etravirine a b
nevirapine a b
b-Blockers carvedilol UGT1A1, UGT2B4, UGT2B7+CYP2D6  
oxprenolol glucuronidation  ↔
Bronchodilators theophylline CYP1A2  ↔
Contraceptives/HRT oestradiol CYP3A4, CYP1A2+glucuronidation  
ethinyloestradiol CYP3A4.CYP2C9, glucuronidation  
norethisterone CYP3A4, glucuronidation  
Cytotoxics anastrozole CYP3A4+UGT1A4  
dacarbazine CYP1A2.CYP2E1  ↔
droloxifene glucuronidation  ↔
epirubicin UGT2B7  ↔
formestane partly glucuronidation  ↔
procarbazine CYP2B6, CYP1A2  ↔
Gastrointestinal agents alosetron CYP1A2.CYP2C9, CYP3A4  ↔
Antihypertensives irbesartan glucuronidation+CYP2C9  ↔
labetalol UGT1A1, UGT2B7  ↔
losartan CYP2C9  ↔
torasemide CYP2C9  ↔
Immunosuppressants mycophenolate UGT1A9, UGT2B7  ↔
Lipid-lowering agents gemfibrozil UGT2B7  ↔
pitavastatin UGT1A3, UGT2B7.CYP2C9, CYP2C8  ↔
Continued
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Table 2. Continued
Therapeutic class Drug Metabolic pathway/comments Ritonavir Cobicistat
Anti-Parkinson agents apomorphine glucuronidation, sulphation  ↔
rasagiline CYP1A2  ↔
ropinirole CYP1A2  ↔
Other dexmedetomidine UGT1A4, UGT2B10, CYP2A6  ↔
HRT, hormone replacement therapy; UGT, uridine diphosphate-glucuronosyltransferase; , potential increase in co-medication exposure by ritonavir or
cobicistat pharmacokinetic boosting; , potential decrease in co-medication exposure by ritonavir or cobicistat pharmacokinetic boosting; ↔, no
clinically significant effect on co-medication exposure.
Information on the metabolic pathway of the co-medication and on the description of the DDI can be found at the Liverpool HIV Drug Interactions
web site.20
aCoadministration is possible when using 600/100 mg of darunavir/ritonavir twice daily, but it is not recommended with 300/100 mg of atazanavir/
ritonavir once daily.
bNot recommended to be given with once-daily boosting with cobicistat (i.e. 150 mg once daily); cobicistat is not sufficient to overcome the induction
effect of efavirenz, etravirine or nevirapine. Of note: cobicistat is not licensed as a twice-daily boosting agent.
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